North America Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

Published: November 30, 2021 |

KBV Research | 71 Pages | Delivery time: 1-2 business days

Price

Description
Table of Contents
List of Tables

Add to Compare

The North America Filgrastim Market would witness market growth of 7.3% CAGR during the forecast period (2021-2027).

Filgrastim is majorly given for neutropenia that is caused by bone marrow transplantation and chemotherapy in patients. It is one of the supportive therapies used in numerous kinds of cancers. In the past few years, cancer prophylaxis has significantly increased in various developed nations and many governments have taken supportive initiatives for creating awareness and educating people about its early treatment. Thus, such aspects are estimated to propel the growth of the filgrastim market over the forecast period.

Approved biosimilars like Neukine, Colstim, Grafeel, and Filcad that are comparatively inexpensive and widely available in emerging nations, thereby augment the growth of the filgrastim market during the forecast period.

The strong healthcare system of various developed nations of this region including the US and Canada is estimated to fuel the growth of the regional filgrastim market over the forecast period. Factors like the increasing prevalence of chronic diseases and the growing geriatric populations are anticipated to augment the growth of the regional filgrastim market in the coming years.

The presence of various key market players in this region along with the increasing investment in R&D activities to develop more effective products would accelerate the growth of the regional market. In addition, supportive reimbursement policies of the governments in this region, are motivating patients to get their treatment and thus, opening the growth avenues for the players operating in the regional market.

The US market dominated the North America Filgrastim Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $266.7 million by 2027. The Canada market is poised to grow at a CAGR of 9.7% during (2021 - 2027). Additionally, The Mexico market is would showcase a CAGR of 8.7% during (2021 - 2027).

Based on Drug Type, the market is segmented into Biosimilar and Biologic. Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksoz Group

Scope of the Study

Market Segments covered in the Report:

By Drug Type

Biosimilar and
Biologic

By Indication

Chemotherapy induced Neutropenia
Chronic Neutropenia and
Other Indications

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies and
Online Pharmacies

By Country

US
Canada
Mexico
Rest of North America

Companies Profiled

Abbott Laboratories
Amgen, Inc.
Pfizer, Inc.
Novartis AG
Dr. Reddy's Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
Kyowa Kirin Co., Ltd. (Kirin Company)
Cadila Healthcare Ltd. (Zydus Cadila)
Apotex, Inc.
Toksoz Group

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 North America Filgrastim Market, by Drug Type
- 1.4.2 North America Filgrastim Market, by Indication
- 1.4.3 North America Filgrastim Market, by Distribution Channel
- 1.4.4 North America Filgrastim Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction
- 2.1.1 Overview
  - 2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints

Chapter 3. North America Filgrastim Market by Drug Type

3.1 North America Biosimilar Market by Country
3.2 North America Biologic Market by Country

Chapter 4. North America Filgrastim Market by Indication

4.1 North America Chemotherapy induced Neutropenia Market by Country
4.2 North America Chronic Neutropenia Market by Country
4.3 North America Other Indications Market by Country

Chapter 5. North America Filgrastim Market by Distribution Channel

5.1 North America Hospital Pharmacies Market by Country
5.2 North America Retail Pharmacies Market by Country
5.3 North America Online Pharmacies Market by Country

Chapter 6. North America Filgrastim Market by Country

6.1 US Filgrastim Market
- 6.1.1 US Filgrastim Market by Drug Type
- 6.1.2 US Filgrastim Market by Indication
- 6.1.3 US Filgrastim Market by Distribution Channel
6.2 Canada Filgrastim Market
- 6.2.1 Canada Filgrastim Market by Drug Type
- 6.2.2 Canada Filgrastim Market by Indication
- 6.2.3 Canada Filgrastim Market by Distribution Channel
6.3 Mexico Filgrastim Market
- 6.3.1 Mexico Filgrastim Market by Drug Type
- 6.3.2 Mexico Filgrastim Market by Indication
- 6.3.3 Mexico Filgrastim Market by Distribution Channel
6.4 Rest of North America Filgrastim Market
- 6.4.1 Rest of North America Filgrastim Market by Drug Type
- 6.4.2 Rest of North America Filgrastim Market by Indication
- 6.4.3 Rest of North America Filgrastim Market by Distribution Channel

Chapter 7. Company Profiles

7.1 Abbott Laboratories
- 7.1.1 Company Overview
- 7.1.2 Financial Analysis
- 7.1.3 Segmental and Regional Analysis
- 7.1.4 Research & Development Expense
7.2 Amgen, Inc.
- 7.2.1 Company Overview
- 7.2.2 Financial Analysis
- 7.2.3 Regional Analysis
- 7.2.4 Research & Development Expenses
7.3 Pfizer, Inc.
- 7.3.1 Company Overview
- 7.3.2 Financial Analysis
- 7.3.3 Regional Analysis
- 7.3.4 Research & Development Expense
- 7.3.5 Recent strategies and developments:
  - 7.3.5.1 Approvals and Trials:
7.4 Novartis AG
- 7.4.1 Company Overview
- 7.4.2 Financial Analysis
- 7.4.3 Segmental and Regional Analysis
- 7.4.4 Research & Development Expense
- 7.4.5 Recent strategies and developments:
  - 7.4.5.1 Product Launches and Product Expansions:
7.5 Dr. Reddy's Laboratories Ltd.
- 7.5.1 Company Overview
- 7.5.2 Financial Analysis
- 7.5.3 Segmental and Regional Analysis
- 7.5.4 Research & Development Expense
- 7.5.5 Recent strategies and developments:
  - 7.5.5.1 Partnerships, Collaborations, and Agreements:
  - 7.5.5.2 Product Launches and Product Expansions:
7.6 Teva Pharmaceutical Industries Ltd.
- 7.6.1 Company Overview
- 7.6.2 Financial Analysis
- 7.6.3 Regional Analysis
- 7.6.4 Research & Development Expenses
- 7.6.5 Recent strategies and developments:
  - 7.6.5.1 Approvals and Trials:
7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
- 7.7.1 Company Overview
- 7.7.2 Financial Analysis
- 7.7.3 Regional Analysis
- 7.7.4 Research & Development Expense
- 7.7.5 Recent strategies and developments:
  - 7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Cadila Healthcare Ltd. (Zydus Cadila)
- 7.8.1 Company Overview
- 7.8.2 Financial Analysis
- 7.8.3 Segmental and Regional Analysis
- 7.8.4 Research & Development Expense
7.9 Apotex, Inc.
- 7.9.1 Company Overview
- 7.9.2 Recent strategies and developments:
  - 7.9.2.1 Product Launches and Product Expansions:
7.1 Toksoz Group
- 7.10.1 Company Overview

LIST OF TABLES

TABLE 1 North America Filgrastim Market, 2017 - 2020, USD Million
TABLE 2 North America Filgrastim Market, 2021 - 2027, USD Million
TABLE 3 North America Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 4 North America Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 5 North America Biosimilar Market by Country, 2017 - 2020, USD Million
TABLE 6 North America Biosimilar Market by Country, 2021 - 2027, USD Million
TABLE 7 North America Biologic Market by Country, 2017 - 2020, USD Million
TABLE 8 North America Biologic Market by Country, 2021 - 2027, USD Million
TABLE 9 North America Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 10 North America Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 11 North America Chemotherapy induced Neutropenia Market by Country, 2017 - 2020, USD Million
TABLE 12 North America Chemotherapy induced Neutropenia Market by Country, 2021 - 2027, USD Million
TABLE 13 North America Chronic Neutropenia Market by Country, 2017 - 2020, USD Million
TABLE 14 North America Chronic Neutropenia Market by Country, 2021 - 2027, USD Million
TABLE 15 North America Other Indications Market by Country, 2017 - 2020, USD Million
TABLE 16 North America Other Indications Market by Country, 2021 - 2027, USD Million
TABLE 17 North America Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 18 North America Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 19 North America Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 20 North America Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 21 North America Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 22 North America Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 23 North America Online Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 24 North America Online Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 25 North America Filgrastim Market by Country, 2017 - 2020, USD Million
TABLE 26 North America Filgrastim Market by Country, 2021 - 2027, USD Million
TABLE 27 US Filgrastim Market, 2017 - 2020, USD Million
TABLE 28 US Filgrastim Market, 2021 - 2027, USD Million
TABLE 29 US Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 30 US Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 31 US Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 32 US Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 33 US Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 34 US Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 35 Canada Filgrastim Market, 2017 - 2020, USD Million
TABLE 36 Canada Filgrastim Market, 2021 - 2027, USD Million
TABLE 37 Canada Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 38 Canada Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 39 Canada Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 40 Canada Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 41 Canada Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 42 Canada Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 43 Mexico Filgrastim Market, 2017 - 2020, USD Million
TABLE 44 Mexico Filgrastim Market, 2021 - 2027, USD Million
TABLE 45 Mexico Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 46 Mexico Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 47 Mexico Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 48 Mexico Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 49 Mexico Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 50 Mexico Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 51 Rest of North America Filgrastim Market, 2017 - 2020, USD Million
TABLE 52 Rest of North America Filgrastim Market, 2021 - 2027, USD Million
TABLE 53 Rest of North America Filgrastim Market by Drug Type, 2017 - 2020, USD Million
TABLE 54 Rest of North America Filgrastim Market by Drug Type, 2021 - 2027, USD Million
TABLE 55 Rest of North America Filgrastim Market by Indication, 2017 - 2020, USD Million
TABLE 56 Rest of North America Filgrastim Market by Indication, 2021 - 2027, USD Million
TABLE 57 Rest of North America Filgrastim Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 58 Rest of North America Filgrastim Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 59 Key Information - Abbott Laboratories
TABLE 60 Key Information - Amgen, Inc.
TABLE 61 Key Information - Pfizer, Inc.
TABLE 62 Key Information - Novartis AG
TABLE 63 key information - Dr. Reddy's Laboratories Ltd.
TABLE 64 Key Information - Teva Pharmaceuticals Industries Ltd.
TABLE 65 Key Information - Kyowa Kirin Co., Ltd.
TABLE 66 Key Information - Cadila Healthcare Ltd.
TABLE 67 Key Information - Apotex, Inc.
TABLE 68 Key Information - Toksoz Group